Al-Dojaily Yasir, Feldman Steven R
Dr. Al-Dojaily is with the Department of General Surgery at Wake Forest University School of Medicine in Winston-Salem, North Carolina.
Dr. Feldman is with the Department of Dermatology at the Center for Dermatology Research at Wake Forest University School of Medicine in Winston-Salem, North Carolina; the Department of Pathology at Wake Forest University School of Medicine in Winston-Salem, North Carolina; and the Department of Social Sciences and Health Policy at Wake Forest University School of Medicine in Winston-Salem, North Carolina.
J Clin Aesthet Dermatol. 2025 Jul 1;18(7):12-16.
This review aims to understand medication adherence and its influence on efficacy for existing and novel topical treatments for molluscum contagiosum.
A PubMed search was performed on clinical studies from 2000 to 2023 assessing adherence and treatment efficacy for topical and non-topical therapies used to treat molluscum.
Adherence to individual topical treatments for molluscum is poor and limits their utility in clinical practice, despite demonstrated safety, painless administration, and advantages for pediatric and home use. Studies suggested lower adherence for topical rather than procedural treatments due to delayed effects, long treatment duration, and uncertain perceived benefits. New topical agents, VP-102 (ie, cantharidin 0.7% drug-device combination) and SB206 (ie, berdazimer gel 10.3%), showed promising efficacy in clinical trials, but their ability to address adherence is unclear.
There is a lack of sufficient clinical studies on topical medications for molluscum contagiosum, limiting our overall understanding of adherence and practical efficacy.
Several studies suggest that commonly used topical medications for molluscum suffer from poor adherence, reducing treatment efficacy. Addressing adherence to these medications may promote the utility of topicals to deliver the need for safe, painless, and efficacious treatments for molluscum. Larger, well-designed trials accounting for adherence are needed before evidence-based treatment recommendations can be made for topical molluscum treatments. Our findings propose that in-office topicals like cantharidin may overcome nonadherence and enhance efficacy compared to daily home-administered topical medications.
本综述旨在了解现有和新型传染性软疣局部治疗方法的用药依从性及其对疗效的影响。
对2000年至2023年评估用于治疗传染性软疣的局部和非局部疗法的依从性和治疗效果的临床研究进行了PubMed检索。
尽管已证明局部治疗传染性软疣的安全性、无痛给药以及对儿科和家庭使用的优势，但对个体局部治疗的依从性较差，限制了它们在临床实践中的应用。研究表明，由于效果延迟、治疗持续时间长以及感知益处不确定，局部治疗的依从性低于程序性治疗。新的局部用药，VP - 102（即0.7%斑蝥素药物装置组合）和SB206（即10.3%贝达齐默凝胶）在临床试验中显示出有前景的疗效，但其解决依从性问题的能力尚不清楚。
关于传染性软疣局部用药的临床研究不足，限制了我们对依从性和实际疗效的整体理解。
多项研究表明，常用的传染性软疣局部用药依从性差，降低了治疗效果。解决这些药物的依从性问题可能会提高局部用药的实用性，满足对传染性软疣进行安全、无痛且有效治疗的需求。在能够基于证据对传染性软疣局部治疗提出建议之前，需要进行更大规模、设计良好且考虑到依从性的试验。我们的研究结果表明，与每日在家使用的局部用药相比，像斑蝥素这样的门诊局部用药可能会克服不依从性并提高疗效。
